Replies to post #1907 on VistaGen Therapeutics Inc (VTGN)

[Investman432]

Desperate times drive some CEOs to do desperate things. John DeLorean dealt coke to raise money for his car company. Singh is caught in a bad place, but his biggest issue is making payroll. How has the company addressed its cash deficit during 2013? There is only so long a company can survive on fumes and promises. I suspect VSTA has reverted to bare bones IP platform with little if any actual operations.

These past eight week, Singh has had plenty of time to properly size up BGMO --- yet somehow he has confidence there will be closing in June. This means he is in denial of reality and should not be running a company. You have to admit, Herzog must be one helluva good liar to keep rolling Singh and Platinum after three air balls.

[Investman432]

The next filing from VSTA will be 8-k to announce 10-k won't be filed on time. Hard to get audit when company has no money to pay accountant.

I am surprised the share price has held, given the vacuum of information on how company is paying its current operating expenses. Loyal shareholders are not willing to cut and run.

If I were Platinum, I'd be hard at work to merge VSTA into another biotech company which has better business/funding capabilities. It's no fun being only deep pocket behind cash sinkhole with no clear time line on producing cash. Especially since the VSTA story has gotten old.

Yes, VSTA raised $50 mm of grants/investment over 15 years -- but where are the commercial products and steady licensing income that should be happening by now? Time has unfortunately shown VSTA doesn't have cutting edge products that are in high demand or offer potential for breakthrough discoveries. All there is is a few ancillary JVs that use stem lines but not assaying IP, and one Phase Ib stage drug of uncertain commercial attraction.

Dribbling in more money behind this management team is folly -- the choice is to sell the IP or merge into another biotech or just close down.